Moreover, this PML risk panel test was positive for 10.9% of PML cases in our study (Table 5), which is higher than the presence of BRCA1 and BRCA2 variants in breast cancer patients (2.8 and 2.7%, respectively) (53). Here, BRCA1 is linked to progressive multifocal leukoencephalopathy.